Shanghai IxCell Biopharmaceutical

IxCell Biopharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on developing innovative off-the-shelf cell therapies. The company utilizes a proprietary induced pluripotent stem cell (iPSC) platform to produce standardized, high-quality therapeutic cells, including natural killer (iNK) cells and mesenchymal stem cells (iMSCs). Their lead programs target hematologic malignancies, solid tumors, and immune-related disorders, aiming to provide more accessible and cost-effective alternatives to autologous CAR-T therapies. IxCell maintains integrated R&D and GMP-compliant manufacturing capabilities to support its clinical pipeline. The leadership team comprises experts with extensive experience in stem cell biology and translational medicine. The company is positioned as a pioneer in the Chinese iPSC-derived cell therapy sector.